Durect Corp (DRRX) 1.37 $DRRX
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit Meeting
PR Newswire - Wed May 07, 7:30AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco. The summit is an effort to bring together senior policymakers, medical professionals, educators, local, state and federal law enforcement and the community to seek solutions to this problem and to raise awareness of the issue.
Technical Data on Top Gainers -- Research on MeetMe, Cerus, Durect, and Omeros
PR Newswire - Tue May 06, 12:38PM CDT
The US markets saw a positive sentiment on Monday, May 05, 2014, with the NASDAQ Composite closing at 4,138.06, up 0.34%, the Dow Jones Industrial Average ending the session at 16,530.55, up 0.11% and the S&P 500 edging 0.19% higher to finish the trading session at 1,884.66. The session saw a positive impact from Energy, Health Care and Utilities sectors along with a drag from Financials and Consumer Staples sectors. A number of stocks saw large movements, including MeetMe Inc. (NASDAQ: MEET), Cerus Corporation (NASDAQ: CERS), Durect Corporation (NASDAQ: DRRX) and Omeros Corporation (NASDAQ: OMER). Free technical research on MEET, CERS, DRRX and OMER can be downloaded upon signing up at:
Transdermal Drug Delivery Market & Clinical Pipeline Insight Report 2014 - Detailed Analysis of the $25 Billion Industry
M2 - Fri May 02, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdr2kp/transdermal_drug) has announced the addition of the "Transdermal Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation. Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations. Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance. There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe. Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life. Key Topics Covered: 1. Introduction to Transdermal Drug Delivery 2. Transdermal Drug Delivery Mechanism 3. Why Need For Transdermal Drug Delivery? 4. Transdermal Drug Delivery Market Outlook 5. Transdermal Drug Delivery Market Dynamics 6. Future of Transdermal Drug Delivery Market 7. Guidelines/Regulations for Transdermal Drug Delivery 8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications 9. Marketed Transdermal Drug Profiles 10. Suspended & Discontinued Transdermal Drug Profiles 11. Competitive Landscape - Acrux, - ANI Pharmaceuticals - Antares Pharma - Bayer HealthCare Pharmaceuticals - Dermatrends Inc - Durect Corporation - Nuvo Research - Novartis - Phosphagenics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/bd...ermal_drug
DURECT Corporation Announces First Quarter 2014 Financial Results and Update of Programs
PR Newswire - Thu May 01, 3:05PM CDT
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014. Total revenues were $6.3 million and net loss was $3.6 million for the three months ended March 31, 2014 as compared to total revenues of $4.2 million and net loss of $5.2 million for the three months ended March 31, 2013.
DURECT Corporation Invites You to Join its First Quarter 2014 Earnings Conference Call
PR Newswire - Wed Apr 23, 4:40PM CDT
In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 1, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
DURECT Announces POSIDUR(TM) (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting
PR Newswire - Tue Apr 01, 3:15PM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR(TM) (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. The meeting will be held on April 3-6 at the Sheraton Chicago Hotel and Towers in Chicago.
Lifshitz & Miller Law Firm Announces Investigation of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. and NII Holdings, Inc.
PR Newswire - Tue Mar 18, 3:01PM CDT
CytRx Corporation
Harwood Feffer LLP Announces Investigation of DURECT Corporation
PR Newswire - Fri Mar 07, 8:00PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against DURECT Corporation ("DURECT" or the "Company"
(NASDAQ: DRRX) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
Robbins Arroyo LLP Is Investigating the Officers and Directors of DURECT Corporation on Behalf of Shareholders
PR Newswire - Thu Mar 06, 6:30PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of the pharmaceutical company, DURECT Corporation (NasdaqGM: DRRX), breached their fiduciary duties to shareholders.
DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs
PR Newswire - Thu Feb 27, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013. Total revenues were $4.3 million for the three months ended December 31, 2013 as compared to $3.3 million for the three months ended December 31, 2012. Net loss was $5.1 million for the three months ended December 31, 2013 as compared to a net loss of $5.5 million for the same period in 2012.
Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of DURECT Corporation
PR Newswire - Thu Feb 20, 7:45AM CST
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of DURECT Corporation ("DURECT" or the "Company" (NasdaqGM -DRRX). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
DURECT CorporationCorporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:55PM CST
The following issues have been halted by IIROC:
DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference
PR Newswire - Tue Feb 18, 7:30AM CST
In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
America's Top 5 Health Threats in 2014
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 16, 11:31AM CST
According to the World Health Organization, as of 2011 there were 12,420 different diseases, disorders, and ailments that can afflict the human body. This cornucopia of diseases and disorders ranges from more of the nuisance variety to...
This Week in Biotech: Three Strikes and You're Out!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 15, 1:10PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DURECT Corporation - DRRX
PR Newswire - Fri Feb 14, 1:56PM CST
Pomerantz LLP is investigating claims on behalf of investors of DURECT Corporation ("DURECT" or the "Company" (NasdaqGS: DRRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit Meeting
PR Newswire - Wed May 07, 7:30AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco. The summit is an effort to bring together senior policymakers, medical professionals, educators, local, state and federal law enforcement and the community to seek solutions to this problem and to raise awareness of the issue.
Technical Data on Top Gainers -- Research on MeetMe, Cerus, Durect, and Omeros
PR Newswire - Tue May 06, 12:38PM CDT
The US markets saw a positive sentiment on Monday, May 05, 2014, with the NASDAQ Composite closing at 4,138.06, up 0.34%, the Dow Jones Industrial Average ending the session at 16,530.55, up 0.11% and the S&P 500 edging 0.19% higher to finish the trading session at 1,884.66. The session saw a positive impact from Energy, Health Care and Utilities sectors along with a drag from Financials and Consumer Staples sectors. A number of stocks saw large movements, including MeetMe Inc. (NASDAQ: MEET), Cerus Corporation (NASDAQ: CERS), Durect Corporation (NASDAQ: DRRX) and Omeros Corporation (NASDAQ: OMER). Free technical research on MEET, CERS, DRRX and OMER can be downloaded upon signing up at:
Transdermal Drug Delivery Market & Clinical Pipeline Insight Report 2014 - Detailed Analysis of the $25 Billion Industry
M2 - Fri May 02, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdr2kp/transdermal_drug) has announced the addition of the "Transdermal Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation. Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations. Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance. There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe. Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life. Key Topics Covered: 1. Introduction to Transdermal Drug Delivery 2. Transdermal Drug Delivery Mechanism 3. Why Need For Transdermal Drug Delivery? 4. Transdermal Drug Delivery Market Outlook 5. Transdermal Drug Delivery Market Dynamics 6. Future of Transdermal Drug Delivery Market 7. Guidelines/Regulations for Transdermal Drug Delivery 8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications 9. Marketed Transdermal Drug Profiles 10. Suspended & Discontinued Transdermal Drug Profiles 11. Competitive Landscape - Acrux, - ANI Pharmaceuticals - Antares Pharma - Bayer HealthCare Pharmaceuticals - Dermatrends Inc - Durect Corporation - Nuvo Research - Novartis - Phosphagenics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/bd...ermal_drug
DURECT Corporation Announces First Quarter 2014 Financial Results and Update of Programs
PR Newswire - Thu May 01, 3:05PM CDT
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014. Total revenues were $6.3 million and net loss was $3.6 million for the three months ended March 31, 2014 as compared to total revenues of $4.2 million and net loss of $5.2 million for the three months ended March 31, 2013.
DURECT Corporation Invites You to Join its First Quarter 2014 Earnings Conference Call
PR Newswire - Wed Apr 23, 4:40PM CDT
In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 1, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
DURECT Announces POSIDUR(TM) (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting
PR Newswire - Tue Apr 01, 3:15PM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR(TM) (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. The meeting will be held on April 3-6 at the Sheraton Chicago Hotel and Towers in Chicago.
Lifshitz & Miller Law Firm Announces Investigation of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. and NII Holdings, Inc.
PR Newswire - Tue Mar 18, 3:01PM CDT
CytRx Corporation
Harwood Feffer LLP Announces Investigation of DURECT Corporation
PR Newswire - Fri Mar 07, 8:00PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against DURECT Corporation ("DURECT" or the "Company"
(NASDAQ: DRRX) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws. Robbins Arroyo LLP Is Investigating the Officers and Directors of DURECT Corporation on Behalf of Shareholders
PR Newswire - Thu Mar 06, 6:30PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of the pharmaceutical company, DURECT Corporation (NasdaqGM: DRRX), breached their fiduciary duties to shareholders.
DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs
PR Newswire - Thu Feb 27, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013. Total revenues were $4.3 million for the three months ended December 31, 2013 as compared to $3.3 million for the three months ended December 31, 2012. Net loss was $5.1 million for the three months ended December 31, 2013 as compared to a net loss of $5.5 million for the same period in 2012.
Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of DURECT Corporation
PR Newswire - Thu Feb 20, 7:45AM CST
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of DURECT Corporation ("DURECT" or the "Company"
(NasdaqGM -DRRX). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. DURECT CorporationCorporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:55PM CST
The following issues have been halted by IIROC:
DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference
PR Newswire - Tue Feb 18, 7:30AM CST
In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
America's Top 5 Health Threats in 2014
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 16, 11:31AM CST
According to the World Health Organization, as of 2011 there were 12,420 different diseases, disorders, and ailments that can afflict the human body. This cornucopia of diseases and disorders ranges from more of the nuisance variety to...
This Week in Biotech: Three Strikes and You're Out!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 15, 1:10PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DURECT Corporation - DRRX
PR Newswire - Fri Feb 14, 1:56PM CST
Pomerantz LLP is investigating claims on behalf of investors of DURECT Corporation ("DURECT" or the "Company"
(NasdaqGS: DRRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. 
